ArticleMultiple sclerosis and related disorders2024
Frailty in multiple sclerosis: A scoping review.
Article in Multiple sclerosis and related disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07521982 (Comparison of Frailty, Physical Fitness Parameters, and Irisin Levels Between Patients With Multiple Sclerosis and Healthy Volunteers), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Frailty, Physical Fitness Parameters, and Irisin Levels Between Patients With Multiple Sclerosis and Healthy Volunteers
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Measures of Comorbidities and Frailty in Multiple Sclerosis-Systematic Review on Evidence and Applicability of Utilized Scoring Systems in Clinical Routine and Real-World Data.European journal of neurology · 2025Pooled it
- Reducing frailty in frail people with multiple sclerosis: Feasibility of a 6-week multimodal exercise training program.PloS one · 2026Trial
- Delivering high-quality multiple sclerosis care in Germany: challenges and regional models.Neurological research and practice · 2026Review
- Review
- Preventing frailty in multiple sclerosis is a realistic goal - No.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Frailty Exacerbates Disability in Progressive Multiple Sclerosis.Annals of clinical and translational neurology · 2026Article
- Guiding Multiple Sclerosis Care: An Update to the 2013 Consensus Statement from the MS in the 21st Century Steering Group.Neurology and therapy · 2026Article
- Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practice.Therapeutic advances in neurological disorders · 2026Article
- Frailty and its association with mental health and quality of life in multiple sclerosis: A cross-sectional study.Sage open chronic diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This scoping review aims to provide a comprehensive overview of frailty in multiple sclerosis (MS), building upon the increasing number of studies that have recently begun to explore the potential impact of this age-related condition on the lives of people with MS (pwMS). A systematic search was conducted on PubMed, Scopus, Embase, Ovid MEDLINE, CINAHL, CENTRAL, Web of Science, PEDRO, and clinicaltrials.gov. The search results were limited to studies published between 2000 and 2024 without language restrictions. After the screening process, 11 studies (10 original articles and one conference paper) met the inclusion criteria and were included. The scope of the included studies was mainly aimed at quantifying frailty levels and prevalence in pwMS, investigating the association between MS clinical characteristics and frailty, and exploring the relationship between frailty and adverse clinical outcomes in pwMS. All studies concluded that frailty is highly prevalent in MS, with prevalences ranging from 17 % to 66 % (ambulatory patients only) and that pwMS have an early onset of frailty compared to the general non-MS population, as the mean age of the included participants ranged from 41.2 ± 9.0 to 58.6 ± 6.0 years. Higher disability levels, disease duration, and progressive MS subtypes were commonly associated with frailty. In addition, several studies showed that frailty was strongly associated with reduced walking performance, lower sleep quality, fatigue, lower quality of life, falls, primary care visits, and mortality. In conclusion, frailty represents a common yet underinvestigated clinical concern for the MS community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.